Tevogen Bio rises on revenue forecast of nearly $1 bln
21/10/2024 21:37
** Shares of drug developer Tevogen Bio TVGN.O closed up
about 5% at $1.80
** Company forecasts top line revenue for its specialty care
pipeline to be nearly $1 bln in its launch year
** Cumulative 5-year revenue estimate between $18 bln
and $22 bln - TVGN
** Company's pipeline includes treatment for Covid-19
infection in patients with certain cancers, as well as arthritis
** Up to last close, stock was down 84.2% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))